Paper Review — verify claims with raw data

Evidence synthesis (visual -> short bullets)

• Scope: Price et al. synthesize early experimental studies showing Cas9-based inhibition of DNA viruses (HBV, HPV, EBV), retroviruses (HIV provirus disruption and host-receptor editing), plant DNA viruses (geminiviruses), and preliminary RNA-targeting strategies (FnCas9 with a PAMmer) Price et al., 2016 — scope summary
• What worked experimentally: localized / ex vivo editing and reporter assays show robust target disruption; plant transgenics achieved functional viral resistance; small-animal hydrodynamic plasmid delivery produced transient HBV reductions — none achieved sterilizing, systemic cures in immunocompetent hosts Price et al., 2016 — experimental outcomes
• Core mechanistic basis: programmable DNA cleavage by SpCas9 (guide RNA + PAM recognition; HNH and RuvC cleavage domains) — foundational biochemistry is cited (Jinek et al. 2012), which the review assumes as platform technology Jinek et al., 2012 — Cas9 programmable nuclease

Critical appraisal — strengths

• Comprehensive 2016-era synthesis connecting mechanistic CRISPR biology to antiviral use-cases across taxa, with accurate citations to contemporaneous experimental studies Price et al., 2016 — strengths
• Balanced discussion of key translational bottlenecks (delivery, immune response to bacterial proteins, off-target risks, viral escape), not overstating therapeutic readiness Price et al., 2016 — limitations discussion

Critical appraisal — limitations, blindspots & updates since 2016

1. Delivery remains the dominant translational barrier: the review correctly flags that AAV/lentivirus have cargo or tropism limits and that systemic modification of all infected cells (e.g., >10^11 CD4+ T cells in humans) is unrealistic with 2016 vectors; subsequent work (2016–2026) has reinforced these constraints and developed new vectors and nonviral nanoparticles, but no universal delivery solution has been validated clinically for systemic antiviral genome editing Price et al., 2016 — delivery limits
2. Immunogenicity and safety: the authors appropriately call out potential humoral and cellular immune responses to bacterial Cas9 proteins and AAV vectors; later human and preclinical data (not in this 2016 review) confirm pre-existing anti-Cas9 immunity is common, supporting the caution the paper voices (immune clearance, need for transient or immune-evasive designs). The review does not have later human immunogenicity datasets (post-2016) but anticipates the issue Price et al., 2016 — immunogenicity caution
3. Off-target and genomic safety: the review surveys existing methods to improve specificity (paired nickases, truncated gRNAs, engineered high-fidelity Cas9) and cites early specificity work (e.g., Ran et al., 2013; Fu et al., 2014; Kleinstiver et al., 2015). The authors’ concern that off-target cleavage could be deleterious is well-founded; since 2016, improved nucleases and unbiased off-target assays have advanced but have not eliminated risk in therapeutic contexts Price et al., 2016 — off-target discussion
4. Viral escape dynamics: the review mentions multiplexed gRNAs to delay escape, but empirical long-term evolution data were limited in 2016; this remains a key unknown for direct antiviral targeting — host-factor targeting (e.g., CCR5) trades viral-escape risk for potential host side-effects and irreversibility of edits (ethical/clinical considerations).
5. Evidence-grade: the review synthesizes mostly in vitro and short-term animal-model studies; clinical-grade evidence is absent (appropriately). The authors avoid overclaiming; their translational optimism is cautious and conditional on solving delivery/immunogenicity and specificity hurdles Price et al., 2016 — evidence-grade

Where the review is right — and what would overturn its central conclusions

Correct predictions / enduring points:

• Cas9 is versatile: programmable DNA/RNA targeting enables multiple antiviral strategies (direct genome cleavage, host factor editing, transcriptional modulation) — confirmed by many follow-up studies and later ortholog discoveries Jinek et al., 2012 — Cas9 foundation
• Delivery, immunogenicity, off-targets and viral escape are the gating challenges — the review highlighted these and proposed sensible mitigation strategies (split-Cas9, smaller Cas proteins, ex vivo editing, multiplexing) that remain the central translational levers.

What would disprove the paper’s central translational optimism:

• Robust evidence that systemic delivery of Cas9:gRNA cannot be achieved safely at required scale for clearing persistent viral reservoirs in vivo (e.g., inability to transduce relevant tissues without unacceptable immunotoxicity) would falsify therapeutic feasibility.
• Demonstration that Cas9-induced edits consistently create oncogenic or deleterious off-target changes in clinically relevant models at therapeutic doses would undercut safety claims.

Practical recommendations for follow-up research (concise)

1. Prioritize delivery research: develop tissue-selective, repeat-dosable, low-immunogenic vectors (novel AAV capsids, lipid nanoparticles, cell-targeting ligands) and benchmark transduction efficiency in reservoir-relevant tissues.
2. Immunology-first studies: map human anti-Cas9 B- and T-cell epitopes across populations; test transient expression systems and immune-evasive Cas variants in preclinical nonhuman primate models.
3. Resistance/escape modeling: experimentally evolve viruses under multiplexed-gRNA pressure to measure time-to-escape and find conserved, low-escape-rate viral targets or optimal host-factor targets with acceptable safety profiles.
4. Rigorous off-target quantification: combine unbiased genome-wide assays (GUIDE-seq, SITE-Seq, CIRCLE-Seq) with long-term functional assays in primary cells and organoids at therapeutically relevant doses.

Minimal, falsifiable hypotheses inspired by the review

1. Multiplexed Cas9 targeting of highly conserved regions across HIV subtypes plus host immune reactivation will reduce viral rebound probability in a humanized mouse model versus single-site targeting (testable, falsifiable).
2. Transient Cas9 RNP delivery to hepatocytes using targeted LNPs can reduce HBV cccDNA copy number per cell by >50% in an immunocompetent large-animal model without durable anti-Cas9 adaptive immunity (testable, falsifiable).

Final balanced take

Price et al. (2016) delivered a carefully argued, well-sourced review that correctly anticipated the main translational bottlenecks for Cas9 antiviral use and proposed reasonable mitigation strategies. The paper’s novelty (2016) was high for consolidating disparate antiviral use cases; scientific quality is strong as a review, but the underlying experimental evidence then available remained preclinical and incomplete for clinical translation. The review remains useful as a roadmap and checklist for required engineering and safety studies.